ubet63 ph

VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “ Company ”, “ Rakovina ”, or “ Rakovina Therapeutics ”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the closing of a $3.0 million private placement. The private placement consists of 50,000,000 units (the “ Units ”) at a price of $0.06 per Unit. Each Unit consists of one common share of the Company (each, a “ Common Share ”) and one Common Share purchase warrant (each, a “ Warrant ”). Each Warrant entitles the holder thereof to subscribe for and purchase one Common Share of the Company for a period of 24 months from the date of issue at a price of $0.10 per Common Share. Rakovina retains the right to accelerate the Warrant exercise period if, upon written notice to the holder, the 20-day volume-weighted average price of its Common Shares exceeds $0.30. In connection with the Private Placement, the Company paid cash finder’s fees to Canaccord Genuity Corp., Ventum Financial Corp., Haywood Securities Inc., Research Capital Corporation, Hampton Securities Limited, Ewing Morris & Co. Investment Partners Ltd. and Leede Financial Inc. (each a “ Finder ”, and collectively, the “ Finders ”) in the aggregate amount of $180,841 and issued a total of 3,021,872 non-transferable finder’s warrants (each, a “ Finder’s Warrant ’) to the Finders, in accordance with the policies of the TSX Venture Exchange (the “ TSXV ”). Each Finder’s Warrant entitles the holder thereof to subscribe for and purchase one Common share of the Company for a period of 24 months from the date of issue at a price of $0.10 per Common Share, subject to acceleration on the same terms as the Warrants issued in connection with the private placement. The private placement is subject to the final acceptance of the TSXV and all securities issuable in connection with the private placement are subject to a hold period of four months plus one day from the date of issuance, in accordance with applicable securities laws. The proceeds of the private placement will be used to accelerate both discovery and development of the Company’s proprietary drug candidates, shortlisted from the Deep Docking and Variational AI platforms. “This overwhelming response from our investors underscores the strength of our science, the extraordinary talent and dedication of our team and the transformative potential of our therapies,” said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. “We are deeply grateful for the trust placed in us and remain resolute in our mission to utilize leading AI technologies to develop innovative solutions for cancer care.” The Company extends its heartfelt thanks to its investors, partners, and team for their unwavering support as Rakovina continues its work to bring new hope to patients and families affected by cancer. Rakovina is pleased to announce its engagement of Fairfax Partners Inc. as its Investor Relations (IR) partner. With extensive expertise in investor engagement strategies, Fairfax will implement a comprehensive six-month IR program designed to enhance Rakovina’s market presence and expand its investor base. The program, which includes an option to renew for an additional six months, focuses on complementing traditional IR efforts with targeted online marketing campaigns, activation of a robust social media influencer network, and collaboration with external consultants and global wealth management channels. These initiatives will support Rakovina’s strategic plan for 2025 by institutionalizing its investor base and strengthening its distribution capabilities. Under the agreement, Fairfax will receive a monthly fee of $5,000 plus GST, a one-time setup fee of $15,000 plus GST, and a marketing budget of $120,000 plus GST, disbursed as follows: $80,000 upon signing and $40,000 two months later. Services provided by Fairfax include inbound and outbound phone communications, website and social media management, marketing material preparation, news release support, and roadshow assistance, ensuring Rakovina’s IR efforts align with market expectations. Fairfax Partners Inc., located at 306-1238 Seymour Street, Vancouver, BC, confirms that neither its directors nor officers hold any securities of Rakovina. For inquiries, please contact connect@fairfaxpartners.com. “We are thrilled to partner with the seasoned team at Fairfax Partners to expand our investor base and increase awareness of Rakovina Therapeutics’ vision. Fairfax’s creative and forward-thinking approach to investor relations will be a critical asset as we enter a pivotal year. By harnessing their extensive network and digital expertise, we aim to significantly enhance our market presence and deliver lasting value to our shareholders,” said Mr. Bacha. About Rakovina Therapeutics Inc. Rakovina Therapeutics Inc. is dedicated to developing innovative cancer therapies targeting the DNA-damage response. The company has established a development pipeline of novel DNA-damage response inhibitors by leveraging Artificial Intelligence (AI) to accelerate the identification and optimization of drug candidates. Rakovina Therapeutics aims to advance one or more of these candidates into human clinical trials in collaboration with pharmaceutical partners and secure marketing approvals from Health Canada, the U.S. Food and Drug Administration, and other international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com . The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Forward-Looking Statements: This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the terms of the private placement, the closing of the private placement, the receipt of final TSXV approval, the proposed business plan of the Company; the Company’s commitment to advancing new cancer therapies; the ability of the Company to extract value from its AI collaborations; the Company’s ability to execute on its business plans while maintaining high standards of research; the ability of Pharma Inventor Inc. to accurately provide medicinal chemistry support; the projected timeline and effectiveness of the Company’s strategy to utilize the Deep Docking AI platform; and the Company’s ability to generate shareholder value. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedar.com. For Further Information Contact: David Hyman, Chief Financial Officer info@rakovinatherapeutics.com Invest Relations &Media Michelle Seltenrich ir@rakovinatherapeutics.com 778-773-5432Mutual of America Capital Management LLC boosted its stake in Tenable Holdings, Inc. ( NASDAQ:TENB – Free Report ) by 10.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 81,167 shares of the company’s stock after purchasing an additional 7,713 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Tenable were worth $3,289,000 as of its most recent filing with the Securities & Exchange Commission. A number of other hedge funds have also added to or reduced their stakes in the stock. Mitsubishi UFJ Trust & Banking Corp boosted its stake in Tenable by 20.6% during the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 11,482 shares of the company’s stock valued at $568,000 after buying an additional 1,958 shares during the period. Vanguard Group Inc. boosted its position in shares of Tenable by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 12,543,352 shares of the company’s stock valued at $620,018,000 after acquiring an additional 32,535 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of Tenable by 815.9% during the first quarter. Acadian Asset Management LLC now owns 21,799 shares of the company’s stock worth $1,076,000 after purchasing an additional 19,419 shares in the last quarter. Bessemer Group Inc. increased its position in shares of Tenable by 60.2% in the first quarter. Bessemer Group Inc. now owns 21,060 shares of the company’s stock worth $1,041,000 after purchasing an additional 7,910 shares during the last quarter. Finally, American International Group Inc. raised its stake in Tenable by 1.0% in the first quarter. American International Group Inc. now owns 57,385 shares of the company’s stock valued at $2,837,000 after purchasing an additional 592 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock. Insider Activity In other news, CFO Stephen A. Vintz sold 3,413 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $41.75, for a total value of $142,492.75. Following the sale, the chief financial officer now directly owns 278,493 shares of the company’s stock, valued at $11,627,082.75. This represents a 1.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website . Also, CEO Amit Yoran sold 5,673 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $41.75, for a total transaction of $236,847.75. Following the completion of the transaction, the chief executive officer now owns 39,309 shares of the company’s stock, valued at approximately $1,641,150.75. The trade was a 12.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here . In the last 90 days, insiders have sold 22,307 shares of company stock valued at $920,880. Corporate insiders own 4.30% of the company’s stock. Analyst Ratings Changes Read Our Latest Analysis on Tenable Tenable Stock Performance NASDAQ:TENB opened at $42.44 on Friday. The company has a quick ratio of 1.28, a current ratio of 1.28 and a debt-to-equity ratio of 0.88. Tenable Holdings, Inc. has a twelve month low of $35.25 and a twelve month high of $53.50. The stock has a market cap of $5.10 billion, a P/E ratio of -83.31 and a beta of 0.83. The firm’s fifty day simple moving average is $40.96 and its 200 day simple moving average is $41.79. Tenable Company Profile ( Free Report ) Tenable Holdings, Inc provides cyber exposure solutions for in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and Japan. Its platforms include Tenable Vulnerability Management, a cloud-delivered software as a service that provides organizations with a risk-based view of traditional and modern attack surfaces; Tenable Cloud Security, a cloud-native cloud security solutions for security teams to continuously assess the security posture; Tenable Identity Exposure, a solution to secure Active Directory environments; Tenable Web App Scanning, which provides scanning for modern web applications; Tenable Lumin Exposure View, a measurement tool; Tenable Attack Surface Management, an external attack surface management solution; Tenable Security Center, an on-premises solution that provides a risk-based view of an organization’s IT, security and compliance posture; and Tenable OT Security, an operational technology security solution which provides threat detection, asset tracking, vulnerability management, and configuration control capabilities. Read More Want to see what other hedge funds are holding TENB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tenable Holdings, Inc. ( NASDAQ:TENB – Free Report ). Receive News & Ratings for Tenable Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenable and related companies with MarketBeat.com's FREE daily email newsletter .GSA Capital Partners LLP acquired a new stake in shares of The Southern Company ( NYSE:SO – Free Report ) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 3,345 shares of the utilities provider’s stock, valued at approximately $302,000. Other hedge funds have also bought and sold shares of the company. Acadian Asset Management LLC boosted its stake in shares of Southern by 1,361.6% during the first quarter. Acadian Asset Management LLC now owns 3,201 shares of the utilities provider’s stock valued at $229,000 after purchasing an additional 2,982 shares during the period. Quadrature Capital Ltd purchased a new stake in shares of Southern during the first quarter valued at $1,168,000. 1832 Asset Management L.P. boosted its stake in shares of Southern by 11.9% during the first quarter. 1832 Asset Management L.P. now owns 30,938 shares of the utilities provider’s stock valued at $2,219,000 after purchasing an additional 3,293 shares during the period. LRI Investments LLC purchased a new stake in shares of Southern during the first quarter valued at $88,000. Finally, Kestra Advisory Services LLC boosted its stake in shares of Southern by 17.3% during the first quarter. Kestra Advisory Services LLC now owns 278,880 shares of the utilities provider’s stock valued at $20,007,000 after purchasing an additional 41,161 shares during the period. Institutional investors own 64.10% of the company’s stock. Insider Activity In related news, CEO James Y. Kerr II sold 30,000 shares of the stock in a transaction that occurred on Friday, October 4th. The shares were sold at an average price of $89.64, for a total value of $2,689,200.00. Following the transaction, the chief executive officer now owns 145,088 shares in the company, valued at approximately $13,005,688.32. This represents a 17.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link . Also, EVP Bryan D. Anderson sold 6,565 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $89.54, for a total transaction of $587,830.10. Following the completion of the transaction, the executive vice president now owns 44,467 shares in the company, valued at approximately $3,981,575.18. This trade represents a 12.86 % decrease in their position. The disclosure for this sale can be found here . Corporate insiders own 0.18% of the company’s stock. Southern Stock Performance Southern ( NYSE:SO – Get Free Report ) last posted its quarterly earnings data on Thursday, October 31st. The utilities provider reported $1.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.33 by $0.10. Southern had a net margin of 17.87% and a return on equity of 12.78%. The firm had revenue of $7.27 billion for the quarter, compared to the consensus estimate of $7.14 billion. During the same quarter in the prior year, the company posted $1.42 earnings per share. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. Research analysts expect that The Southern Company will post 4.04 EPS for the current fiscal year. Southern Announces Dividend The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 6th. Stockholders of record on Monday, November 18th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Monday, November 18th. This represents a $2.88 annualized dividend and a dividend yield of 3.29%. Southern’s dividend payout ratio (DPR) is currently 66.98%. Wall Street Analysts Forecast Growth A number of analysts have recently issued reports on the stock. UBS Group boosted their target price on shares of Southern from $90.00 to $91.00 and gave the company a “neutral” rating in a research note on Friday, September 20th. Scotiabank upped their price objective on shares of Southern from $87.00 to $96.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, August 20th. Barclays upped their price objective on shares of Southern from $71.00 to $83.00 and gave the stock an “equal weight” rating in a research note on Tuesday, October 15th. Jefferies Financial Group assumed coverage on shares of Southern in a research note on Friday, September 20th. They issued a “hold” rating and a $94.00 price objective for the company. Finally, Bank of America upped their price objective on shares of Southern from $86.00 to $87.00 and gave the stock a “neutral” rating in a research note on Thursday, August 29th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $89.47. Check Out Our Latest Analysis on Southern About Southern ( Free Report ) The Southern Company, through its subsidiaries, engages in the generation, transmission, and distribution of electricity. The company also develops, constructs, acquires, owns, and manages power generation assets, including renewable energy projects and sells electricity in the wholesale market; and distributes natural gas in Illinois, Georgia, Virginia, and Tennessee, as well as provides gas marketing services, gas distribution operations, and gas pipeline investments operations. Further Reading Five stocks we like better than Southern What Are Dividends? Buy the Best Dividend Stocks Tesla Investors Continue to Profit From the Trump Trade What is a Low P/E Ratio and What Does it Tell Investors? MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally Are Penny Stocks a Good Fit for Your Portfolio? Netflix Ventures Into Live Sports, Driving Stock Momentum Want to see what other hedge funds are holding SO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Southern Company ( NYSE:SO – Free Report ). Receive News & Ratings for Southern Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Southern and related companies with MarketBeat.com's FREE daily email newsletter .I bought a $5 lottery ticket on a whim and scored $50k – my family thought ‘I’d gone crazy’ after what happened nextubet63 ph 。

Canadian fund drops bid for Spanish pharma firm GrifolsEagles look to clinch NFC East title while Cowboys hope to play spoiler

When dockworkers walked the picket line in October, the strike lasted for 3 days. And if a new contract between their 45,000 member union and the U.S. Maritime Alliance isn't signed by mid-January — a longer strike could send inflation going in the wrong direction. Just months after a strike at Gulf and East Coast ports ended, operators and union members are now at an impasse — once again — over automation. Port operators say they need more technology to increase port efficiency, improve safety and to control costs. But union members say no, because some workers will lose their jobs. A new strike could come if an agreement isn't reached by January 15. And if that happens inflation could increase, when goods aren't flowing in an out of ports as quickly. Thursday union leaders met with President-elect Donald trump at Mar-a-Lago and walked away with his support. Writing about automation on Truth social, Trump said "the amount of money saved is nowhere near the distress, hurt, and harm it causes for American workers," and that foreign countries "...shouldn't be looking for every last penny knowing how many families are hurt." RELATED STORY | Billions of dollars of U.S. economic activity halted as port workers enter day two of their strike Professor Todd Belt of George Washington University called it Trump striking a different path than he did during his first term. "During the first Trump term you had Donald Trump, surrounded by a lot of people who were suggested to him by incumbent Republicans who had really a Republican orthodoxy on free trade. Donald trump now is going to be surrounded by a lot of people who support his ideas of interventionism and tariffs, as well as other trade policies that will protect working people at the expense of, of course, inflation," Belt said. The International Longshoremen's Association has until Jan. 15 to negotiate a new contract with the U.S. Maritime Alliance, which represents ports and shipping companies. At the heart of the dispute is whether ports can install automated gates, cranes and container-moving trucks that could make it faster to unload and load ships. The union argues that automation would lead to fewer jobs, even though higher levels of productivity could do more to boost the salaries of remaining workers. The Maritime Alliance said in a statement that the contract goes beyond ports to "supporting American consumers and giving American businesses access to the global marketplace — from farmers, to manufacturers, to small businesses, and innovative start-ups looking for new markets to sell their products." "To achieve this, we need modern technology that is proven to improve worker safety, boost port efficiency, increase port capacity, and strengthen our supply chains," said the alliance, adding that it looks forward to working with Trump. In October, the union representing 45,000 dockworkers went on strike for three days, raising the risk that a prolonged shutdown could push up inflation by making it difficult to unload container ships and export American products overseas. The issue pits an incoming president who won November's election on the promise of bringing down prices against commitments to support blue-collar workers along with the kinds of advanced technology that drew him support from Silicon Valley elite such as billionaire Elon Musk. Trump sought to portray the dispute as being between U.S. workers and foreign companies, but advanced ports are also key for staying globally competitive. China is opening a $1.3 billion port in Peru that could accommodate ships too large for the Panama Canal. There is a risk that shippers could move to other ports, which could also lead to job losses. Mexico is constructing a port that is highly automated, while Dubai, Singapore and Rotterdam already have more advanced ports. "For the great privilege of accessing our markets, these foreign companies should hire our incredible American Workers, instead of laying them off, and sending those profits back to foreign countries," Trump posted. "It is time to put AMERICA FIRST!" The Associated Press contributed to this report.

Donald Trump Calls On Feds To Either Explain The Mystery Drones Or Shoot Them DownNeurocrine Biosciences Announces FDA Approval of CRENESSITYTM (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal HyperplasiaNone